| Transaction Date | Recipient | Shares | Type | Price | Value |
|---|---|---|---|---|---|
| 30th September 2020 | Mark A Goldsmith | 42,548 | Exercise of derivative | $4.73 | $201,252.04 |
| 30th September 2020 | Mark A Goldsmith | 1,312 | Open or private sale | $34.12 | $44,762.29 |
| 30th September 2020 | Mark A Goldsmith | 42,578 | Open or private sale | $34.40 | $1,464,853.51 |
| 30th September 2020 | Mark A Goldsmith | 30 | Exercise of derivative | $1.12 | $33.60 |
| 29th September 2020 | Mark A Goldsmith | 21,088 | Open or private sale | $34.08 | $718,651.63 |
| 29th September 2020 | Mark A Goldsmith | 20,076 | Exercise of derivative | $4.73 | $94,959.48 |
| 29th September 2020 | Mark A Goldsmith | 30,523 | Open or private sale | $34.14 | $1,041,917.87 |
| 29th September 2020 | Mark A Goldsmith | 10,447 | Exercise of derivative | $4.09 | $42,728.23 |
| 28th September 2020 | Mark A Goldsmith | 10,132 | Exercise of derivative | $4.09 | $41,439.88 |
| 28th September 2020 | Mark A Goldsmith | 10,132 | Open or private sale | $34.11 | $345,567.06 |
Constellation Pharmaceuticals
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.
Constellation Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It engages in the development of novel therapeutics in the field of epigenetics. Its product candidates include CPI-0610, CPI-1205, and CPI-0209.
Ticker: CNST
Sector: Health Technology
Industry: Pharmaceuticals: Major
SEC Central Index Key (CIK): 1434418
Employees: 106
Exchange: NASDAQ
Auditor Opinion:
You must Login to see Language Changes
Disclosure Language changes
You must Login to see analysis
Red Flags
There were no Red Flags found
Fundamentals
Cash at Carrying Value: $179 M (0%)
Marketable Securities, Current: $341 M (588%)
Assets, Current: $523 M (35%)
Property, Plant and Equipment, Net: $1 M (48%)
Assets: $535 M (33%)
Long-term Debt, Current Maturities: $2 M (0%)
Accounts Payable, Current: $6 M (-22%)
Liabilities, Current: $27 M (19%)
Long-term Debt, Excluding Current Maturities: $28 M (0%)
Other Liabilities, Noncurrent: $716 Th (83%)
Liabilities: $63 M (2%)
Common Stock, Value, Issued: $5 Th (25%)
Common Stock, Shares, Issued: $48 M (13%)
Additional Paid in Capital, Common Stock: $846 M (28%)
Retained Earnings (Accumulated Deficit): $375 M (0%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $255 Th (4150%)
Stockholders' Equity (Parent): $472 M (0%)
Liabilities and Equity: $535 M (33%)
Research and Development: $23 M (-47%)
General and Administrative Expenses: $7 M (-45%)
Operating Income/Loss: $30 M (-46%)
Other Income, net: $142 Th (-65%)
Provision for income taxes: $24 Th (-38%)
News
Cronos Is A Buy With Increasing Revenues
18th November 2020
DXP Enterprises Reports Third Quarter 2020 Results
6th November 2020
17 Arrested For Running Fake Call Centre In Delhi: Police
6th November 2020
Ubiquiti Inc. Reports First Quarter Fiscal 2021 Financial Results
6th November 2020